Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Simulation of Airway Deposition of an Aerosol Drug in COPD Patients

Á. Farkas, F. Lizal, J. Jedelsky, J. Elcner, A. Horváth, M. Jicha,

. 2019 ; 11 (4) : . [pub] 20190401

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19029216

Grantová podpora
CZ.02.2.69/0.0/0.0/16_027/0008371 European Union
FSI-S-17-4444 Brno University
INTER-COST LTC17087 Ministry of Education, Youth and Sports of Czech Republic

Medical aerosols are key elements of current chronic obstructive pulmonary disease (COPD) therapy. Therapeutic effects are conditioned by the delivery of the right amount of medication to the right place within the airways, that is, to the drug receptors. Deposition of the inhaled drugs is sensitive to the breathing pattern of the patients which is also connected with the patient's disease severity. The objective of this work was to measure the realistic inhalation profiles of mild, moderate, and severe COPD patients, simulate the deposition patterns of Symbicort® Turbuhaler® dry powder drug and compare them to similar patterns of healthy control subjects. For this purpose, a stochastic airway deposition model has been applied. Our results revealed that the amount of drug depositing within the lungs correlated with the degree of disease severity. While drug deposition fraction in the lungs of mild COPD patients compared with that of healthy subjects (28% versus 31%), lung deposition fraction characteristic of severe COPD patients was lower by a factor of almost two (about 17%). Deposition fraction of moderate COPD patients was in-between (23%). This implies that for the same inhaler dosage severe COPD patients receive a significantly lower lung dose, although, they would need more.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19029216
003      
CZ-PrNML
005      
20190822091711.0
007      
ta
008      
190813s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics11040153 $2 doi
035    __
$a (PubMed)30939795
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Farkas, Árpád $u Centre for Energy Research, Hungarian Academy of Sciences, Konkoly-Thege M. út 29-33, 1121 Budapest, Hungary. farkas.arpad@energia.mta.hu. Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. farkas.arpad@energia.mta.hu.
245    10
$a Simulation of Airway Deposition of an Aerosol Drug in COPD Patients / $c Á. Farkas, F. Lizal, J. Jedelsky, J. Elcner, A. Horváth, M. Jicha,
520    9_
$a Medical aerosols are key elements of current chronic obstructive pulmonary disease (COPD) therapy. Therapeutic effects are conditioned by the delivery of the right amount of medication to the right place within the airways, that is, to the drug receptors. Deposition of the inhaled drugs is sensitive to the breathing pattern of the patients which is also connected with the patient's disease severity. The objective of this work was to measure the realistic inhalation profiles of mild, moderate, and severe COPD patients, simulate the deposition patterns of Symbicort® Turbuhaler® dry powder drug and compare them to similar patterns of healthy control subjects. For this purpose, a stochastic airway deposition model has been applied. Our results revealed that the amount of drug depositing within the lungs correlated with the degree of disease severity. While drug deposition fraction in the lungs of mild COPD patients compared with that of healthy subjects (28% versus 31%), lung deposition fraction characteristic of severe COPD patients was lower by a factor of almost two (about 17%). Deposition fraction of moderate COPD patients was in-between (23%). This implies that for the same inhaler dosage severe COPD patients receive a significantly lower lung dose, although, they would need more.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lizal, Frantisek $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. lizal@fme.vutbr.cz.
700    1_
$a Jedelsky, Jan $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. jedelsky@fme.vutbr.cz.
700    1_
$a Elcner, Jakub $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. elcner@fme.vutbr.cz.
700    1_
$a Horváth, Alpár $u Chiesi Hungary Ltd., Dunavirág u. 2, 1138 Budapest, Hungary. a.horvath@chiesi.com. Department of Pulmonology, County Institute of Pulmonology, 2045 Törökbálint, Hungary. a.horvath@chiesi.com.
700    1_
$a Jicha, Miroslav $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. jicha@fme.vutbr.cz.
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 11, č. 4 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30939795 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822091950 $b ABA008
999    __
$a ind $b bmc $g 1434365 $s 1067676
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c 4 $e 20190401 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a CZ.02.2.69/0.0/0.0/16_027/0008371 $p European Union
GRA    __
$a FSI-S-17-4444 $p Brno University
GRA    __
$a INTER-COST LTC17087 $p Ministry of Education, Youth and Sports of Czech Republic
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...